INFLUENCE OF POPULATION IMMUNITY PECULIARITIES ON THE STRUCTURE OF MEASLES AND RUBELLA PREVALENCE

Cover Page


Cite item

Full Text

Abstract

According to the lasting serological investigations of patients with rubella and measles, a major factor that determines the resistance to the infections is specific antibodies, that are still circulating in blood of recovered persons during their life. Since vaccinated people are also included in this concept, serological monitoring of people different ages who get vaccinated against rubella and measles is conducted in Russia. However the discrepancy between specific immunity intensity and the measles incidence was showed last years. Using “Vector Best” kits, the study of the anti-measles and antirubella population immunity in scale of age: under 1 year, 1–2 years, 3–6 years, 7–14 years, 15–17 years, 18–30 years, 31–40 years, 41–50 years, and 51–60 years was carried out in Moscow and Moscow region in 2013 (period of unfavorable epidemic situation). The serum probes were obtained from 654 random healthy donors and 646 patients with serologically confirmed measles infection. As a result, gradual increase of percentage of people with protective antibodies to rubella and measles have been demonstrated: 81.3% donors aged 7–14 years were protected from measles and more than 90% — from rubella. Moreover, percentage of individuals who have had immunity to rubella were the same in adults too. The most marked increase of percentage of seronegative persons to measles virus (40% and more) was in age from 18 to 30 years, and in groups over the age 40 years old protection reaches 85–95%. Comparison between percentage of measles patients different ages and percentage of persons with protective antibodies in serum have demonstrated significant negative correlation between measles prevalence and the level of specific antibody in population (r = –0.76). According to the results, increase (to 28%) and decrease (to 2.9%) of measles patients aged 18 to 30 and 51 to 60 years are based on decrease (to 55%) and increase (to 95%) of persons with protective immunity, respectively. Results of analysis of measles prevalence in different ages have demonstrated, that among adult measles patients (18–50 years) 14.5% responded on infection by secondary immune response; among children and teenagers there were no such patients, that proves the significant effectiveness of prophylactic vaccines.

About the authors

A. P. Toptygina

.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Lomonosov Moscow State University.

Author for correspondence.
Email: toptyginaanna@rambler.ru

PhD, MD (Medicine), Leading Researcher, Laboratory of Cytokine; Professor, Department of Immunology.

125212, Russian Federation, Moscow, Admiral Makarov str., 10.

Phone: (495) 452-18-01 (office).

Fax: (495) 452-18-30.

Россия

M. A. Smerdova

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology.

Email: fake@neicon.ru

PhD Student, Laboratory of Cytokines.

Moscow.

Россия

M. A. Naumova

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology.

Email: fake@neicon.ru

PhD (Medicine), Senior Researcher, Laboratory of Immunochemistry.

Moscow. Россия

N. P. Vladimirova

Centre for Hygiene and Epidemiology in Moscow.

Email: fake@neicon.ru

Virologist, Laboratory of Virology.

Moscow.

Россия

T. A. Mamaeva

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology.

Email: fake@neicon.ru

PhD (Biology), Leading Researcher, Laboratory of Immunochemistry.

Moscow. Россия

References

  1. Мамаева Т.А., Железнова Н.В., Наумова М.А., Говорухина М.В., Калашникова Н.А., Бичурина М.А., Мукомолов С.Л. Алгоритм лабораторного подтверждения и дифференциальной диагностики коревой инфекции в период элиминации кори в Российской Федерации // Инфекция и иммунитет. 2015. Т. 5, № 1. С. 55–62.
  2. МУ 3.1.2943-11 «Организация и проведение серологического мониторинга и состояния коллективного иммунитета к инфекциям, управляемым средствами специфической профилактики (дифтерия, столбняк, коклюш, корь, краснуха, эпидемический паротит, полиомиелит, гепатит В)»
  3. Попова А.Ю., Бичурина М.А., Лаврентьева И.Н., Железнова Н.В., Антипова А.Ю., Щербакова С.А., Буаро М.Й., Тотолян А.А. Изучение уровня иммунитета к вирусу кори в отдельных группах населения Гвинейской Республики в рамках глобальной программы элиминации кори. Сообщение 1 // Инфекция и иммунитет. 2016. Т. 6, № 4. С. 353–358.
  4. Самойлович Е.О. Надзор за корью в Республике Беларусь: подготовка к верификации элиминации инфекции // Медицинский журнал. 2014. № 2. С. 94–99.
  5. Топтыгина А.П. Общие закономерности формирования и поддержания специфического гуморального иммунного ответа на примере ответа на вирусы кори и краснухи // Инфекция и иммунитет. 2014. Т. 4, № 1. С. 7–14.
  6. Топтыгина А.П., Мамаева Т.А., Алешкин В.А. Особенности специфического гуморального иммунного ответа против вируса кори // Инфекция и иммунитет. 2013. Т. 3, № 3. С. 243–250.
  7. Топтыгина А.П., Семикина Е.Л., Алешкин В.А. Формирование и поддержание специфического клеточного ответа на вакцинацию «Приорикс» // Иммунология. 2013. Т. 34, № 5. С. 257–261.
  8. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: Measles — monitoring European outbreaks, 7 July 2017. Stockholm: ECDC. URL: https://ecdc.europa.eu/en/news-events/epidemiological-update-measles-monitoringeuropean-outbreaks-7-july-2017 (Accessed 31 Aug 2017).
  9. Filia A., Bella A., Del Manso M., Baggieri M., Magurano F., Rota M.C. Ongoing outbreak with well over 4,000 measles cases in Italy from January to end August 2017 — what is making elimination so difficult? Euro Surveill., 2017, vol. 22 (37), p. 30614. doi: 10.2807/1560-7917.ES.2017.22.37.30614
  10. Hickman C.J., Hyde T.B., Sowers S.B., Mercader S., McGrew M., Williams N.J., Beeler J.A., Audet S., Kiehl B., Nandy R., Tamin A., Bellini W.J. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J. Infect. Dis. 2011, vol. 204, suppl. 1, pp. 549–558. doi: 10.1093/infdis/jir106
  11. Orenstein W.A., Strebel P.M., Papania M., Sutter R.W., Bellini W.J., Cochi S.L. Measles eradication: is it in our future? Am. L. Public Health., 2000, vol. 90, pp. 1521–1525.
  12. Tischer A., Gassner M., Richard J.-L., Suter-Riniker F., Mankertz A., Heininger U. Vaccinated students with negative enzyme immunoassay results show positive measles virus- specific antibody levels by immunof luorescence and plaque neutralization test. J. Clin. Virol., 2007, vol.38, pp. 204–209. doi: 10.1016/j.jcv.2006.12.017
  13. WHO. Manual for the laboratory diagnosis of measles and rubella virus infection; 2 ed. Geneva, Switzerland: WHO, 2006, pp. 58–65.
  14. World Health Organization Regional Office for Europe (WHO/Europe). Fifth Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC) 24–26 October 2016, Copenhagen, Denmark. Copenhagen: WHO/Europe. URL: http://www.euro.who.int/__data/assets/pdf _ file/0005/330917/5th-RVC-meeting-report.pdf?ua=1 (Accessed 31 Aug 2017).

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Toptygina A.P., Smerdova M.A., Naumova M.A., Vladimirova N.P., Mamaeva T.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies